PR Newswire All News ReleasesCodex · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 04:00:00·⟳ 抓取 04:00:13 +13s·⚡ 决策 08-23 04:02:32 +2m19s·65.6 天前
Kessler Topaz发布Alnylam投资者调查广告，核心事实仍是7月30日TTR收入指引下调
本条信号没有相对7月30日业绩和指引下调的新增可交易事实；律所调查广告本身不足以构成新的强空催化，也不能支持做多反转。
📄 原文PR Newswire All News Releases↗ 原文
RADNOR, Pa., Aug. 22, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized s…
不做 Alnylam Pharmaceuticals, Inc.（ALNY.US）
不做Alnylam Pharmaceuticals, Inc.（ALNY.US）：本条只是律所调查/招揽投资者公告，核心业绩下调和股价大跌已在7月30日发生，缺少新的正式诉讼、监管调查或进一步指引下修；做空催化不够新，做多也无反转依据。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事件正文的核心负面事实是Alnylam已在2026年7月30日披露的TTR产品收入指引下调约2亿美元，以及当日后股价大跌；8月22日PRNewswire只是Kessler Topaz招揽投资者联系律所的调查公告，未披露正式起诉、监管调查、进一步业绩下修或公司确认的新事实。因此当前没有新的方向性edge，回避Alnylam Pharmaceuticals, Inc.（ALNY.US）。
🔎 新鲜度:最早出现 2026-07-30 · 扩散 high · price-in 风险 high ↗
消息传播链
- 2026-07-30首发Alnylam二季度业绩披露声称一手 · 未核验Alnylam披露二季度业绩并下调2026全年TTR净产品收入指引约2亿美元；本条律所广告引用该旧事实。市场反应:正文称该消息后Alnylam股价下跌超过28%。
- Kessler Topaz发布投资者调查/联系律所公告，未给出相对7月30日业绩下调的新经营或监管事实。
关键理由
- 律所调查广告的事实基础是7月30日已公开并已引发股价大幅反应的业绩与指引下调，不是新的经营事件。
- 未披露正式证券集体诉讼、SEC调查、额外赔偿金额或公司新增下修，短线做空强度不足。
- 当前事件没有提供正向反转信息，不能把已跌后的估值修复当成做多催化。
主要风险
- 若后续出现正式起诉、监管调查或公司进一步下调TTR收入指引，需要重新评估Alnylam Pharmaceuticals, Inc.（ALNY.US）的做空与风险信号。
- 本轮因内部stock_tools不可用，未能核验最新报价、市值、20日走势和内部历史案例。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-07-30 · 影响 weakens
核心负面事实是7月30日已发生并已导致股价大幅下跌的旧催化，不支持8月22日再开新空。
检索:Alnylam July 30 2026 lowered TTR product sales guidance $200 million stock fell 28%
先例如何影响了这次决策
对本次决策的影响:先例不足不改变结论；结论由缺少新增事实和price-in风险决定。
方向:未使用外部价格先例定方向；律所调查广告类事件通常需要正式诉讼或监管动作才可能形成独立负面催化。
涨幅量级:无可用高相似、同市场、同相位先例校准涨跌幅；且本次为AVOID，不设置交易幅度。
形态:本条更像旧业绩利空后的二次律所广告扩散，核心风险已由7月30日价格反应消化。
原文全文
展开原文 · 3,064 字
RADNOR, Pa., Aug. 22, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on behalf of investors who purchased or acquired Alnylam Pharmaceuticals, Inc. securities and experienced significant financial losses.
Alnylam Reports Disappointing Financial Results
On July 30, 2026, Alnylam announced its second quarter 2026 financial results. Among other things, Alnylam reported that the company has "lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy." As a result, Alnylam cut its total projected TTR net product revenues by approximately $200 million.
Alnylam's Stock Drops Over 28%
Following the news of Alnylam Pharmaceuticals, Inc.'s poor financial results, the company's stock price fell over 28%.
Investors who purchased Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) securities and experienced losses may have legal rights under the federal securities laws.
CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired Alnylam Pharmaceuticals, Inc. securities and have lost money on your investment, please provide your information here:
https://www.ktmc.com/alnylam-pharmaceuticals-inc-investigation?utm_campaign=hc?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=alny&mktm=PR
There is no cost or obligation to speak with an attorney.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.
CONTACT:
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
[email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
SOURCE Kessler Topaz Meltzer & Check, LLP
Alnylam Reports Disappointing Financial Results
On July 30, 2026, Alnylam announced its second quarter 2026 financial results. Among other things, Alnylam reported that the company has "lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy." As a result, Alnylam cut its total projected TTR net product revenues by approximately $200 million.
Alnylam's Stock Drops Over 28%
Following the news of Alnylam Pharmaceuticals, Inc.'s poor financial results, the company's stock price fell over 28%.
Investors who purchased Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) securities and experienced losses may have legal rights under the federal securities laws.
CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired Alnylam Pharmaceuticals, Inc. securities and have lost money on your investment, please provide your information here:
https://www.ktmc.com/alnylam-pharmaceuticals-inc-investigation?utm_campaign=hc?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=alny&mktm=PR
There is no cost or obligation to speak with an attorney.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.
CONTACT:
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
[email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
SOURCE Kessler Topaz Meltzer & Check, LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。